Hengrui Launches 2026 Global Talent Initiative: 'Gather Global Talents, Inspire the Future!'

Sep 23, 2025 16:17 CST Updated 16:17

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

GSK

Pharmaceutical R&D Manufacturer

Previous Selections

| Research and Innovation |

Hengrui Pharma's Innovative Drug Aireijing® Approved for Treating Relapsed or Refractory Peripheral T-Cell Lymphoma

China's First Approved ADC for HER2-Mutant Non-Small Cell Lung Cancer, Aivida® (艾维达®), Developed by China, Launched

| Internationalization |

Hengrui Pharma's Myosin Inhibitor HRS-1893 Achieves Overseas Licensing!
Hengrui Pharma and GSK Reach Cooperation Agreement to Jointly Develop up to 12 Innovative Drugs Covering Respiratory, Autoimmunity and Inflammation, and Oncology Treatment Areas

| Major Awards |

Good News! Hengrui Pharma's Innovative Drug Hetrombopag Ethanolamine Tablets (Hengqu®) Patent Awarded China Patent Gold Award

Good News! Hengrui Pharma Wins 2023 National Science and Technology Progress Award

| Social Welfare |

"Healthy China Journey: Retracing the Long March" Project Launch Ceremony Successfully Held! Hengrui Pharma Provides Public Welfare Support, Aiding Healthy China

Hengrui Pharma Donates 30 Million Yuan to China Foundation for Poverty Alleviation to Establish "Health Assistance Fund"